A newly developed drug, Vorasidenib, has shown promise in prolonging progression-free survival for patients with a subtype of glioma. The international study found that patients taking Vorasidenib could go nearly 17 more months without their cancer worsening, postponing the need for radiation and chemotherapy.
Targeted Therapy Vorasidenib Offers Hope for Deadly Brain Tumors
Neuroscience News - 5 Jun 2023 00:13
A newly developed drug, Vorasidenib, has shown promise in prolonging progression-free survival for patients with a subtype of glioma. The international study found that patients taking Vorasidenib could go nearly 17 more months without their cancer worsening, postponing the need for radiation and chemotherapy.
Share this Article
Recommended